Related by context. All words. (Click for frequent words.) 62 reversible inhibitor 62 PSN# [002] 62 investigational humanized monoclonal antibody 61 HGS# 60 neratinib 60 orally administered inhibitor 60 hypoxia activated prodrug 60 HGS ETR2 60 JAK inhibitor 60 virus HCV protease inhibitor 59 Zybrestat 59 evaluating tivozanib 59 Carfilzomib 59 elotuzumab 59 pharmacodynamic markers 59 AAG geldanamycin analog 59 cetuximab Erbitux R 59 gemcitabine Gemzar 59 Panzem NCD 58 TLR8 agonist 58 AEG# 58 inverse agonist 58 MORAb 58 HCV NS5B polymerase 58 isoform selective 58 pan histone deacetylase 58 PDE4 inhibitor 58 BRAF inhibitor 58 liposomal formulation 58 CB2 selective receptor agonist 57 lexidronam injection 57 5 HT4 receptor 57 novel histone deacetylase 57 histone deacetylase HDAC inhibitor 57 XL# anticancer compounds 57 investigational hepatitis C 57 PDX pralatrexate 57 PI3K/mTOR 57 FOLFOX6 chemotherapy regimen 57 APPRAISE 57 ZYBRESTAT fosbretabulin 57 receptor tyrosine kinase inhibitor 57 CYP#A# CYP#D# 57 JAK2 inhibitor 57 THR beta agonist 57 inhibitor ARRY 57 TLR9 agonist 57 AEGR 57 sodium glucose cotransporter 57 Oral NKTR 57 PTK# 57 xenograft models 57 Presents Preclinical 56 PROSTASCINT R 56 tolerability pharmacokinetics 56 non nucleoside inhibitor 56 neuropathic pain metabolic diseases 56 small molecule tyrosine 56 TO AVOID PREGNANCY WHILE 56 TLK# 56 compound AEZS 56 JZP 56 Janus kinase 56 novel VDA molecule 56 EndoTAG 56 myelofibrosis polycythemia vera 56 docetaxel Taxotere R 56 IMC A# 56 orally bioavailable 56 oral prodrug 56 PRT# 56 selective kinase inhibitor 56 JAK1 56 kinase inhibition 56 histone deacetylase HDAC 56 metaglidasen 56 demonstrated antitumor activity 56 Cannabinor 56 Aurora Kinase 56 Aplidin 56 neurokinin 1 56 Solorel TM 56 CYT# potent vascular disrupting 56 antisense inhibitors 56 protein tyrosine phosphatase 1B 56 pan HDAC inhibitor 56 IL# PE#QQR 56 histone deacetylase inhibitor 56 Akt inhibitor 56 HDACi 55 DermaVir Patch 55 aurora kinase inhibitor 55 kinase inhibitor 55 candidate REP# 55 small molecule chemotherapeutic 55 targeting CD# 55 JAK3 55 IAP inhibitor 55 Onconase 55 highly selective inhibitor 55 Sudhir Agrawal D.Phil 55 Factor Receptor 55 hypoxia selective 55 HSP# inhibitor 55 selective agonist 55 bevacizumab Avastin R 55 IMiDs R 55 Tyrima 55 Phase Ib clinical trials 55 telomerase inhibitor drug 55 MGd 55 5 HT2A receptor 55 GRN#L 55 proteasome inhibitor 55 Panzem R 55 Kinase Inhibitor 55 DOS# 55 2 methoxyestradiol 55 ENMD # 55 cathepsin K inhibitor 55 5 HT2A serotonin 55 mitogen activated ERK kinase 55 cytokine refractory 55 NS5B polymerase 55 Vaxfectin R 55 Fc fusion protein 55 prognostic biomarker 55 multicenter Phase II 55 HDAC Inhibitor 55 oral picoplatin 55 orally dosed 55 Azedra TM 55 GERD migraine headaches 55 tubulin inhibitor 55 small molecule inhibitor 55 Allovectin 7 ® 54 Intravenous CP 54 SAR# [002] 54 obatoclax GX# 54 SUCCEED trial 54 PNP inhibitor 54 Factor VIIa 54 cortisol synthesis 54 Glufosfamide 54 Trofex ™ 54 mertansine 54 selective antagonist 54 TransVax tm 54 TOCOSOL Camptothecin 54 pharmacodynamic profile 54 entinostat 54 SGLT 54 HGS ETR1 54 PI3 kinase inhibitors 54 generation proteasome inhibitor 54 CCR1 54 5 FU leucovorin 54 factor VIIa 54 hematological tumors 54 preclinically 54 ADP receptor antagonist 54 phase IIb clinical 54 selective inverse agonist 54 Exelixis compounds 54 preclinical efficacy 54 targeted radiotherapeutic 54 epothilones 54 SinuNase ™ 54 phase IIb trial 54 Aurora kinase inhibitor 54 TBC# 54 volociximab 54 indibulin 54 MEK inhibitor 54 deforolimus 54 APD# 54 Tarvacin Anti Cancer 54 seliciclib CYC# 54 ocular formulation 54 selective immunoproteasome inhibitor 54 Epothilone D 54 ZK EPO 54 AKT inhibitor 54 CA4P 54 depsipeptide 54 LEP ETU 54 peptibody 54 PI3K inhibitors 53 siRNA conjugates 53 DGAT 53 RG# ITMN 53 CD4 monoclonal antibody 53 bortezomib Velcade 53 HCV protease 53 ARRY # 53 GMX# 53 generation purine nucleoside 53 LE SN# 53 Trofex TM 53 peripherally acting 53 Hsp# Inhibitor 53 negative allosteric modulator 53 Panzem R NCD 53 SGLT 2 53 Preclinical studies suggest 53 Angiolix 53 HDL Selective Delipidation 53 Panzem 53 Dapagliflozin 53 trial evaluating PRX# 53 IMA# 53 Seliciclib 53 Trastuzumab DM1 53 vascular disrupting agents 53 Initiates Phase II 53 CCR9 antagonist 53 CG# [003] 53 epigenetic therapies 53 Xanafide 53 Phase #b/#a trial 53 OvaRex R 53 mda 7 53 Initiates Clinical Trial 53 Hsp# inhibition 53 GVAX ® 53 cyclin dependent kinases CDKs 53 epithelial tumors 53 non nucleoside HCV 53 ATRA IV 53 tolerability profiles 53 bevacizumab Avastin ® 53 targeted tyrosine kinase 53 PI3K/Akt pathway inhibitor 53 MEK inhibitor RDEA# 53 targeted antifolate 53 anticancer compound 53 certain protein tyrosine 53 davunetide intranasal AL 53 Presents Preclinical Data 53 Kahalalide F 53 novel oral anticoagulant 53 HCV protease inhibitors 53 pralatrexate injection folate analogue 53 potently inhibits 53 Vascular Disrupting Agent 52 TELINTRA R 52 polymerase inhibitor 52 Personalized Immunotherapy 52 pharmacodynamic PD 52 FOLOTYN ® 52 plasma kallikrein inhibitor 52 GSK# [002] 52 multi kinase inhibitor 52 novel anticancer 52 Anavex #-# 52 vinca alkaloid 52 Completes Patient Enrollment 52 Archexin 52 CCR5 antagonist 52 cisplatin gemcitabine 52 humanised antibody 52 mTOR kinase 52 pharmacodynamic effects 52 HCV RNA polymerase 52 deacetylase 52 PORxin TM 52 SCH # 52 sulfonylhydrazine class 52 agonist compounds 52 CCR9 52 Intermezzo ® zolpidem tartrate 52 TKB# 52 peptidomimetic 52 lorvotuzumab mertansine 52 reversible inhibitors 52 Potelligent Technology 52 darinaparsin ZIO 52 MEK inhibitors 52 sapacitabine CYC# 52 novel immunomodulatory 52 VEGF inhibitors 52 HGS ETR1 mapatumumab 52 cell adhesion molecule 52 JAK inhibitors 52 matrix metalloproteases 52 Azedra ™ 52 anti botulism antibody 52 defensin mimetic antibiotic 52 potent antiproliferative 52 Spiegelmer ® 52 dopamine D2 52 INGN 52 Xcytrin R 52 cMet 52 IMPDH inhibitor 52 mGluR5 negative 52 Sphingomab TM 52 personalized immunotherapy 52 IRX 2 52 Romidepsin 52 novel L DOS# 52 fibrotic disease 52 small molecule defensin 52 CCX# 52 Solazed TM 52 immunotoxin 52 lymphoid tumors 52 VQD 52 vitro pharmacology 52 IMiDs ® 52 triciribine phosphate monohydrate 52 Beta catenin pathway 52 Immunotherapeutic 52 biologic therapeutics 52 Maribavir 52 muscarinic receptor agonist 52 poly ADP ribose polymerase 52 antiangiogenic agent 52 Palifosfamide 52 P#X# antagonist 52 VEGF receptor 52 pharmacogenomic translational research 52 mediated inhibition 52 torsemide ER 52 Alfacell proprietary ribonuclease 52 Deforolimus 52 kidney urologic 52 biomodulator 52 preclinical studies Vion 52 folate analogue metabolic 52 2 inhibitor CYT# 52 pharmacodynamic parameters 52 MAb 52 Kosan dependence 51 potently inhibit 51 Trofex 51 Aplidin R 51 MT# MEDI 51 Trandolapril 51 aldehyde dehydrogenase ALDH2 deficiency 51 polysaccharide polymer 51 novel orally administered 51 next generation URAT1 51 p# inhibitor 51 XL# XL# 51 HCV protease inhibitor 51 humanized monoclonal 51 anti fibrotic 51 antiangiogenic 51 GLPG# 51 teplizumab 51 CYT# vascular disrupting 51 tyrosine kinase receptor 51 signal transduction inhibitor 51 NS5b 51 Synavive ™ 51 Selzentry Celsentri 51 FGFR 51 MEND CABG II 51 delafloxacin 51 RAF kinase VEGFR 51 Omacetaxine 51 anaplastic lymphoma kinase ALK 51 mGluR5 antagonists 51 alkylating agent 51 Aurora kinase 51 antiproliferative effects 51 Janus Kinase 51 pathophysiological effects 51 VEGF receptors 51 antitumor effects 51 thymidylate synthase TS 51 DNA methyltransferase inhibitors 51 histone deacetylase 51 cyclophilin inhibitor 51 alpha7 51 Prednisporin 51 selective estrogen receptor modulator 51 NEUGENE antisense 51 pharmacodynamics PD 51 delta isoform 51 antisense oligonucleotide 51 ALN TTR# 51 alpha folate receptor 51 siRNAs targeting 51 selective receptor agonist 51 agent VDA 51 Vidofludimus 51 Eg5 51 positive allosteric modulator 51 Exherin 51 antimitotic 51 pathway inhibitor 51 Flt3 51 HuLuc# 51 Annexin V 51 samarium Sm 51 acetylcholinesterase AChE 51 Genasense ® oblimersen 51 Thalomid R 51 Angiotensin Converting Enzyme 51 CCR2 51 nitric oxide donating prostaglandin 51 anti CD3 51 Reports Preclinical Data 51 oral isotype selective HDAC 51 Elvitegravir 51 orally bioavailable mimics 51 preclinical pharmacology 51 non nucleoside 51 PI3K inhibitor 51 Darapladib 51 nucleotide analog 51 urate lowering 51 RELOVAIR ™ 51 Anticalin R 51 candidate CRLX# 51 targeted nucleotide prodrug 51 REVIVE Diabetes 51 MKC# 51 Genz # 51 potent topoisomerase II 51 selectin antagonist 51 ONCONASE R 51 docetaxel Taxotere ® 51 compound PMX # 50 Insegia 50 initiate Phase 1b 50 novel emulsion formulation 50 LHRH antagonists 50 ALN HPN 50 #ME# 50 Alocrest 50 TLR agonists 50 ACAPODENE TM 50 intranasal formulation 50 sulodexide 50 Histone deacetylase 50 Vascular Wrap TM 50 Phase IIb clinical trials 50 IMiDs ® compound 50 Zemiva TM 50 XOMA 3AB 50 small molecule agonists 50 TRIOLEX ™ 50 Squalamine 50 phosphatidylserine PS targeting 50 JAK#/JAK# 50 selective orally bioavailable 50 agonism 50 NRGN 50 selectively inhibits 50 midstage trials 50 metabotropic glutamate receptor 50 DPP4 inhibitor 50 RNAi therapeutic targeting 50 Interferon beta 50 MGN# 50 HDAC inhibitor 50 Initiates Clinical 50 M1 muscarinic 50 M2 subunit 50 Sapacitabine 50 TG# [003] 50 RH1 targeted chemotherapeutic agent 50 liposome encapsulated 50 Tumour Vascular Disrupting Agent 50 acetonide FA 50 platinum chemotherapeutic 50 novel orally bioavailable 50 ThermoDox R 50 immunomodulating 50 antisense drug 50 Cathepsin S 50 anionic backbone 50 PHX# 50 c Raf kinase 50 MTP inhibitor 50 XP# XP# 50 Annamycin 50 PI3K inhibition 50 TRIOLEX HE# 50 Tß4 50 BiovaxID TM 50 refractory chronic lymphocytic 50 TLR8 50 OMP #M# 50 dihydrochloride 50 BiTE 50 bone morphogenic protein 50 Panzem ® 50 Zoraxel TM 50 Zalypsis 50 IMiD 50 cariprazine 50 Tarvacin TM 50 vascular disrupting agent 50 potency selectivity 50 Studies #CL# #CL# #CL# 50 serine threonine 50 PEGylated irinotecan 50 immunotherapeutic approaches 50 Nasulin ™ 50 initiate Phase IIb 50 introduced NEUGENE 50 anti amnesic 50 Initiate Clinical Trial 50 small molecule thrombopoietin 50 Zemiva ™ 50 Varespladib 49 histone deacetylation 49 pain palliation 49 chemokine receptor 49 cytoprotective 49 RGB # 49 CMV vaccine 49 personalized dendritic 49 therapeutic monoclonal antibody 49 NP2 Enkephalin 49 MKC# MKC# PP 49 hepatocyte growth 49 Fibroblast Growth Factor Receptor 49 Denufosol 49 Cytochrome P# 49 Lixivaptan 49 protein tyrosine kinase 49 subtype selective 49 peptide conjugated 49 carbohydrate polymer 49 neuronal nicotinic receptor NNR 49 Factor Xa inhibitor 49 HQK 49 CORT # 49 PRIMO CABG 49 Eluting Stent 49 carcinogenicity studies 49 benign neoplasms 49 Phase 2b clinical trials 49 RezularTM 49 DNA intercalator 49 Anturol ® 49 specific lectin receptors 49 CRLX# 49 VEGF vascular endothelial 49 peptidic 49 midstage clinical trials 49 Hsp# inhibitor 49 investigational pan BCR 49 Orally administered 49 specific CCR9 antagonist 49 Adenoscan R 49 IL #p# 49 CRTH2 49 neuroprotective properties 49 platform HDL Mimetic 49 Hematide ™ peginesatide 49 Neulasta R 49 Raf kinase 49 HepeX B TM 49 compound perifosine 49 ALN PCS 49 selective androgen receptor modulators 49 TRO# 49 selective adenosine 49 NADiA R 49 Pertuzumab 49 sodium glucose transporter 49 targets Galectin receptors 49 corticosteroid dexamethasone 49 ulimorelin 49 oral proteasome inhibitor 49 cyclic peptide 49 glucagon receptor 49 4 PDE4 enzyme 49 Interferon alpha 49 ® C1 esterase 49 MediGene focuses 49 Phase IIb III 49 monoclonal antibody mAb 49 MEK inhibitor ARRY 49 pharmacologically active isomer 49 delivers fluocinolone acetonide FA 49 Guanilib 49 Initiates Enrollment 49 ISF# 49 retaspimycin 49 humanized monoclonal antibodies 49 BACcel ™ system 49 Upregulation 49 Pharmos proprietary 49 Micromet proprietary BiTE 49 Cloretazine 49 tests miRview TM 49 torezolid 49 IgG1 antibody 49 stable nucleic acid 49 includes TOLAMBA TM 49 potent inhibition 49 candidate ATHX 49 AzaSite Plus 49 investigational HCV polymerase 49 c MET 49 Novolimus 49 Angiocept 49 rxRNA 49 neuropathy sparing 49 potent suppressor 49 vitro cytotoxicity 49 ABL inhibitor 49 RAF kinase 49 KRAS mutation status 49 CTA# 48 omacetaxine mepesuccinate 48 CRMD# 48 placebo controlled multicenter 48 rusalatide acetate 48 Protein Kinase C 48 chimeric monoclonal antibody 48 potent inhibitors 48 Ostabolin C TM 48 FGFR3 48 OncoVEX GM CSF 48 adjuvant GIST 48 lexidronam injection PROSTASCINT 48 HCV replication 48 alkylating 48 chemically modified tetracyclines 48 small molecule activators 48 residual confounding 48 Olaparib 48 protein kinase inhibitor 48 Canvaxin TM 48 selective androgen receptor modulator 48 ongoing Phase IIIb 48 molecular biomarkers 48 Liposomal 48 Systemic Delivery 48 phosphate S1P 48 delipidation 48 sarcoma melanoma 48 heparanase 48 DU #b 48 Allovectin 7 r 48 NS4A 48 thetreatment 48 toenail onychomycosis 48 targeting abnormally proliferating 48 RIGScan CR 48 plasmid DNA vaccine 48 Prodarsan R 48 HEPLISAV ™ 48 Idera Pharmaceuticals 48 Veronate R 48 AZD# ARRY # 48 BFPET 48 Recombinant Human 48 basal insulin analogue 48 ALN TTR 48 chemically modified siRNA 48 Fibrin MB 48 developing Bicifadine serotonin 48 Provenge sipuleucel T 48 Eg5 kinesin spindle 48 Aganocide 48 genomic biomarker 48 pharmacodynamic endpoints 48 accumulate preferentially 48 Files IND 48 PITX2 48 candidate deforolimus 48 SynCon ™ DNA 48 chemoprevention trials 48 Blinatumomab 48 EMPOWER ™ 48 investigational therapies 48 ALV# 48 PEGylated interferon 48 HepaMate 48 TAFA# 48 Parathyroid hormone 48 Elagolix 48 fibrotic disorders 48 BRAF kinase 48 Evoltra ® 48 #beta HSD 1 48 ArQule Kinase Inhibitor Platform 48 cleavable linker 48 obatoclax 48 metabolomic profiles 48 farletuzumab 48 A3 adenosine receptor 48 candidate AP# 48 cytokeratin 48 GEM OS2 48 Aganocide ® 48 deCODE AF TM 48 incyclinide 48 endothelin antagonist 48 Civacir 48 OTCBB PYTO 48 candidates Azedra TM 48 thymidylate synthase 48 Cimzia TM 48 Imprime PGG ® 48 Announces Poster Presentations 48 Atripla combines 48 synthetic siRNA 48 BLOOM DM 48 long acting muscarinic 48 Kiadis 48 highly selective endothelin 48 YONDELIS R 47 Chemokine Therapeutics 47 NASDAQ FLML 47 triple VEGF receptor 47 candidate iSONEP TM 47 HuMax 47 Exherin TM 47 Proc Am Soc 47 EGF receptor 47 CEQ# 47 DiLA2 47 vivo pharmacology 47 ATL/TV# 47 ActA 47 osteogenic 47 vaccine GMK 47 Vaxfectin TM 47 cancer immunotherapies 47 Apaziquone 47 vosaroxin 47 oral salmon calcitonin 47 prokinetic agent 47 Nereus Pharmaceuticals 47 TOCOSOL 47 monoclonal antibody biologic 47 molecular imaging radiopharmaceutical 47 apricitabine ATC 47 γ secretase 47 TPI ASM8 47 GPCR targets 47 investigational pharmacologically unique 47 candidate Liposomal Grb 47 Primary endpoints 47 product platforms AZX# 47 Selective Electrochemical Tumor Ablation 47 geldanamycin 47 staphylococcal vaccine 47 OX1 47 prognostic indicators 47 NXL# 47 Val MARC 47 Gemin X 47 S1P antibody 47 Q#IR 47 initiate Phase IIa 47 DB# [003] 47 OREXIGEN 47 stratifying patients 47 HIV integrase inhibitors 47 nanomolar 47 opioid bowel dysfunction 47 drug zotarolimus 47 Nektar proprietary 47 uricase 47 oral beclomethasone dipropionate 47 romazarit 47 Hormone receptor 47 Anticalin ® 47 HCV NS3 protease 47 Ceflatonin R 47 tivozanib 47 Iluvien ® 47 Lisofylline LSF 47 Neuradiab 47 sodium thiosulfate STS 47 HIV RDEA# 47 bardoxolone 47 developing ViaCyte SM 47 AN# novel 47 Bevirimat 47 malignant mesothelioma Alfacell 47 BLA filing 47 SIX RO ROG 47 tkRNAi 47 HDAC enzymes 47 motexafin gadolinium Injection 47 vascular disrupting 47 Anticalins ® 46 Topoisomerase II 46 DAVANAT 46 5 HT6 46 Cetrorelix 46 Phase III LibiGel 46 candidate ridaforolimus 46 systemic RNAi 46 effector function 46 Fibroblast 46 HDL Mimetic Peptide 46 MEK ERK 46 KL4 Surfactant 46 Augment Injectable 46 recurrent metastatic ovarian cancer 46 polymerase inhibitors 46 naronapride 46 active comparator 46 Mersana Therapeutics 46 HuCAL R 46 LB# [003] 46 lysophosphatidic acid LPA 46 chemokine receptor CCR1 46 allosteric modulator NAM 46 siRNA binds 46 OHR/AVR# 46 Proxinium TM 46 lupus renal disease 46 allosteric modulator 46 Alequel ™ 46 HepDirect prodrug 46 REG1 46 poly ethylene glycol PEG 46 selectin 46 EMPOWER TM 46 Linjeta TM 46 Acetavance TM intravenous acetaminophen 46 multicenter Phase III 46 monoclonal antibody MAb 46 siRNA therapeutic 46 nucleoside 46 prostaglandin synthesis 46 anticancer therapeutics 46 Myocet 46 CB2 selective 46 inhibitor VX 46 Micromet BiTE 46 APEX AMI 46 ORE# 46 tyrosine kinase inhibitor TKI 46 Bruton tyrosine kinase 46 EGFR HER 46 chemotherapy induced neutropenia 46 nasal decolonization 46 predictive biomarker 46 Biopharmaceuticals AG 46 Vascugel 46 proprietary capillary aerosolization 46 inhibitor PPI 46 INT# [002] 46 nitric oxide donating 46 triglyceride lowering 46 enzyme inhibitor 46 Monoclonal 46 small molecule glucokinase 46 CardioPET 46 ionotropic glutamate receptor antagonists 46 proprietary polysaccharide 46 Aptocine 46 treating psychiatric disorders 46 lipid nanoparticles 46 phosphoprotein 46 Pentraxin 2 46 topically applied SEPA 46 QuadraSphere 46 eTag assays 46 AVI RNA based 46 Homspera TM 46 RLY# 46 ghrelin antagonist 46 Protelos 45 Locked Nucleic Acid LNA 45 Regulus Alnylam 45 delivery polymer matrix 45 Zysolin TM 45 SU# [003] 45 apoptosis inducers 45 immatics 45 ritonavir boosted danoprevir 45 Naproxcinod 45 HepeX B 45 EcoNail TM 45 activin receptor type 45 OMS# 45 CBLC# 45 bucindolol hydrochloride 45 NS5A 45 Qutenza TM 45 Fleximer 45 Pervasis 45 Phase #b/#a 45 biostatistical analysis 45 guanosine 45 metabolomic profiling 45 postoperative ileus POI 45 ZFP Therapeutics 45 Vertos II 45 NADiA 45 skeletal sarcomere activators 45 tNOX 45 JUVISTA R Human 45 vivo fluorescence imaging 45 XmAb ™ 45 Endotis 45 unblinding 45 DXL# 45 rPA vaccine candidate 45 vigabatrin GABA aminotransferase inhibitor 45 RNAi Therapeutic 45 sirtuin modulators 45 Nektar pulmonary 45 oncolytic virus 45 Pharmaceutica Ltd. 45 ADME properties 45 ceftazidime 45 lymphatic mapping 45 MB# MB# 45 siRNA mediated 45 ESBA# 45 PrevOnco ™ 45 Ceplene TM 45 picomolar 45 candidate TNFerade biologic 45 neuronal nicotinic receptors NNRs 45 EGFR receptor 45 HCV polymerase 45 Augment TM 45 OXIGON TM 45 Adnectin 45 pafuramidine 45 ACCLAIM II 45 fatty acid amide hydrolase 45 Nanobody ® 45 recombinant plasma 45 Bacterin proprietary 44 SOLTAMOX TM tamoxifen citrate 44 vitro assay 44 DEEP AF 44 orBec ® oral beclomethasone 44 CLIRS trial 44 pyrimidine 44 iobenguane 44 novel antifolate 44 selective adhesion molecule 44 Phase III metastatic melanoma 44 pharmacologic stress 44 PRECISE Trial 44 Gamma secretase 44 Fleximer R 44 Locked Nucleic Acid 44 KL4 surfactant 44 DITPA 44 oxypurinol 44 DELISTING REVIEW 44 novel peptides 44 PI3K AKT 44 Arno Therapeutics 44 synthetic peptides 44 Fodosine 44 Divigel R 44 muscarinic receptor agonists 44 HDL Therapy 44 Sangamo ZFP TF 44 stem cell pluripotency 44 Pentad TM 44 investigational orally administered 44 paclitaxel poliglumex 44 MacuSight 44 nonhormonal treatment 44 confirmatory pivotal 44 NS4B 44 HepDirect 44 ENRICH trial 44 serine protease 44 Levulan ® PDT 44 DUROS 44 Histone Deacetylase 44 pharmacokinetic pharmacodynamic 44 DP VPA 44 Intarcia 44 Aptamer 44 allosteric modulation 44 MDRNA proprietary 44 Celator 44 topical non steroidal 44 co receptor tropism 44 Vivecon 44 ovarian cancer biomarker 43 NTDDS 43 enhance ApoA 43 animal xenograft models 43 PROTECT II 43 CTLA4 Ig product 43 Receptos 43 angiotensin receptor blocker ARB 43 Cyclosert 43 covalently linked 43 polyclonal antibody 43 Trophos 43 ChIP chip 43 orBec R oral beclomethasone